Clinical trials: Refractory to Chemotherapy
Colorectal Cancer
A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer
To assess the safety and tolerability of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy
- Trial name
- NCT01801930
- Testing
- OCV-103 and OCV-104
- Where
- 3 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Multiple Myeloma and Plasma Cell Neoplasm
Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Holmium Ho 166 DOTMP may deliver radiation directly to cancer cells and cause less damage to normal tissue.
- Trial name
- NCT00045136
- Testing
- melphalan, peripheral blood stem cell transplantation, holmium Ho 166 DOTMP
- Where
- 5 sites in United States
- Sponsor
- Poniard Pharmaceuticals
Classical Hodgkin Lymphoma, Relapsed or Refractory Classical Hodgkin Lymphoma
B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes
The purpose of this study is to describe progression-free survival (PFS) in participants with relapsed or refractory classical Hodgkin lymphoma (RRHL), defined as the time from initiation of first treatment for RRHL to first…
- Trial name
- B-HOLISTIC (NCT03327571)
- Where
- South Korea
- Volunteers
- 1,770 people
- Sponsor
- Takeda
Relapsed/Refractory AML
Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
This bridging study will evaluate the efficacy of uproleselan, a specific E-selectin antagonist, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients, compared to chemotherapy alone.
- Trial name
- NCT05054543
- Testing
- Uproleselan
- Where
- 2 sites in China
- Volunteers
- 140 people
- Sponsor
- Apollomics Inc.
Metastatic Breast Cancer, Advanced Breast Cancer
Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment
The purpose of the study is to demonstrate clinical efficacy of the investigational trifunctional bispecific antibody ertumaxomab for treatment of patients with HER-2/neu 1+ or 2+ (FISH-) expressing advanced or metastatic breast…
- Trial name
- NCT00452140
- Testing
- ertumaxomab
- Where
- 5 sites in Austria, France and 3 more
- Volunteers
- 40 people
- Sponsor
- Neovii Biotech
Acute Myeloid Leukemia (AML)
A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated
This is a randomized，multicenter, open-label Phase III, clinical study to confirm the efficacy and safety of SKLB1028 in patients with relapsed or refractory(R/R) FLT3-Mutated Acute Myeloid Leukemia（AML）compared to salvage…
- Trial name
- ALIVE (NCT04716114)
- Testing
- SKLB1028, Salvage Chemotherapy
- Where
- China
- Volunteers
- 315 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
The purpose of this study is to determine if the addition of study drug (custirsen) can provide durable pain palliation for castrate resistant prostate cancer patients receiving docetaxel retreatment or cabazitaxel as a second…
- Trial name
- NCT01083615
- Testing
- custirsen sodium, isotonic, 0.9% sodium chloride, docetaxel
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 14 people
- Sponsor
- Achieve Life Sciences
Astrocytoma, Brain Cancer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers…
- Conditions
- Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer
- Trial name
- NCT04430842
- Testing
- QBS10072S
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Quadriga Biosciences, Inc.
Lymphoma, Follicular
HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab
A Single-Arm, International, Multi-Center Trial of HuMax-CD20 (Ofatumumab), a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Follicular Lymphoma Who Are Refractory to Rituximab as Monotherapy or in Combination With…
- Trial name
- NCT00394836
- Testing
- Ofatumumab
- Where
- United Kingdom
- Volunteers
- 116 people
- Sponsor
- GlaxoSmithKline
Colorectal Cancer Metastatic
Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer
The objective of the program is to provide access to TAS-102 to patients with metastatic colorectal cancer who are refractory to or failing standard chemotherapy, are new to therapy with TAS-102 and in whom therapy with TAS-102…
- Trial name
- NCT02286492
- Testing
- TAS-102
- Where
- 33 sites in United States
- Sponsor
- Taiho Oncology, Inc.